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In vivo T cell preactivation in chronic uremic hemodialyzed and
non-hemodialyzed patients. The production and targeting of a major T
cell derived lymphokine, Interleukin 2 (IL-2), were studied in 23 uremic
patients undergoing regular hemodialysis treatment and 20 uremic
patients prior to the onset of renal replacement therapy. In hemodia-
lyzed patients, abnormally increased proportions of circulating T cells
spontaneously expressing high affinity IL-2 receptors (IL-2 Rec) were
detected; they bound a monoclonal antibody specifically directed to the
IL-2 Rec 55 kDa chain (Tac antigen) (mean SEM: 7.12 0.81% in
patients vs. 2.15 0.39% in normal controls, P < 0.0001) and
significantly proliferated in presence of human recombinant IL-2 alone
(mean sEM: 5438 729 cpm in patients vs. 1647 244 cpm in normal
controls). Hemodialyzed patients also exhibited significantly increased
serum levels of soluble IL-2 receptor (mean SEM: 4036 947 ti/mI in
patients vs. 253 29 U/mI in normal controls, P <0.001). Moreover, a
significantly decreased IL-2 activity was detected in the supernatants of
stimulated T cells from hemodialyzed patients (mean SEM: 0.93
0.12 U/mI in patients vs. 2.49 0.22 U/mI in normal controls, P <
0.0001). In nine hemodialyzed patients who were analyzed before and
immediately after the hemodialysis session no acute modifications of
the various parameters analyzed were detected. Although less pro-
found, a similar pattern of T cell abnormalities was observed in the
uremic non-hemodialyzed patients studied. These data suggest that the
deficient IL-2 activity in uremic patients may be at least in part related
to increased absorption by IL-2 receptor present in abnormally high
amounts on T cells and in the serum. Furthermore, they underline that
although exacerbated by hemodialysis treatment, a latent state of T cell
preactivation is associated with end-stage chronic renal failure.
Chronic renal failure induces a state of immunodeficiency
that mainly involves T cell-mediated immune responses [1—3].
Studies show cutaneous anergy [4], prolonged allograft survival
[5, 6], a decreased antibody response to thymus dependent
antigens like vaccination with HB virus [7—10], influenza virus
[11], as well as an increased incidence of infections not related
to the dialysis treatment such as mycobacterial infections
[12—14]. In spite of progressive improvement over the past few
years of the various methods used for renal replacement ther-
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apy, notably hemodialysis, the immunity of uremic hemodia-
lyzed patients remains poor [15]. The biological in vitro coun-
terpart of this clinically evident immunodeflciency is the low
capacity of purified lymphocytes from uremic patients to re-
spond to antigens, mitogens and monoclonal antibodies trigger-
ing the T3-Ti T cell receptor complex [1—3, 16—18].
Several hypotheses have been put forward to explain the
immunosuppression associated with chronic uremia, including
an intrinsic defect of uremic effector T lymphocytes [19] and/or
the presence of an abnormal immunoregulation mediated by
regulatory T lymphocytes (such as, helper and suppressor T
cells), monocytes or soluble serum factors [20—26].
In a previous report we have shown that uremic hemodia-
lyzed patients present an abnormal bioavailability and targeting
of one major T cell derived soluble factor, namely, interleukin
2 (IL-2) [27], that plays an essential role in cell-mediated
immunity by promoting cell proliferation and differentiation
[281. The preliminary study showed a decreased IL-2 activity in
culture supernatants from stimulated hemodialyzed patients' T
cells [27]. Moreover, uremic hemodialyzed patients presented
high levels of peripheral T cells showing phenotypic and func-
tional signs of preactivation [27]. This particular subset of T
cells spontaneously expressed the interleukin 2 receptor (IL-2
Rec) at their cytoplasmic membrane [27]. The expression of
IL-2 Rec is considered as a marker of activation since it is
absent from normal resting T cells and exclusively appears
following antigenic or mitogenic stimulation [29]. It was sug-
gested that these activated T cells could participate to the
defective IL-2 activity observed in hemodialyzed patients by
promoting increased absorption of the lymphokine.
In the present report our previous results were confirmed and
extended to a larger series of hemodialyzed patients. Moreover,
a group of uremic non-hemodialyzed patients was studied in
parallel, to determine whether the uremic state per se or
changes induced by the hemodialysis procedure could be re-
sponsible for the T cell preactivation observed.
Methods
Patients
Forty-three patients presenting end-stage chronic renal fail-
ure were included in the study.
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Twenty-three of these patients were stabilized on renal
replacement therapy for more than six months prior to the
study. Patients underwent hemodialysis twice a week for four
to five hours using Cuprophan (Hospal, Lyon, France) or
polyacrylonitrile membranes and water pretreated by filtration.
This group of patients included 16 men and 7 women whose
ages ranged from 15 to 74 years old (mean 5EM: 38.7 4.0
years). In these hemodialyzed patients, chronic renal failure
was secondary to chronic glomerulonephritis (9 patients), Al-
port's disease (1 patient), nephroangiosclerosis (3 patients),
chronic instertitial nephritis (3 patients), nephronophitisis (I
patient), congenital malformations (3 patients), diabetic glomer-
ulopathy (1 patient), polycystic kidney disease (I patient) and
renal lithiasis (1 patient). The other 20 patients presented
end-stage renal failure (creatininemia ranging from 460 to 1440
/LM/liter) and were studied before the institution of hemodialy-
sis. This group included 11 men and 9 women, aged 20 to 89
years (mean SEM 55.5 4.8 years). In these patients chronic
renal failure was secondary to chronic glomerulonephritis (5
patients), nephroangiosclerosis (2 patients), congenital malfor-
mation (6 patients), chronic insterstitial nephritis (5 patients)
and polycystic kidney disease (2 patients). Patients in whom
chronic renal failure was secondary to an immunologic disease
were excluded. None of the patients received prior to or during
the study any treatment known to interfere with the immune
system (steroids or other immunosuppressants, /3 blockers,
etc.). At the time of the study none of the patients presented
clinical or biological signs of an evolving infectious process. All
were free of human immunodeficiency virus (HIV) infection.
Concerning hepatitis B (HB) virus infection, one of the
uremic patients not yet on dialysis was positive for HBs antigen
(Ag), one was HBs Ag positive and also presented spontaneous
anti-HBs and anti-HBc antibodies. Two out of the 23 hemodi-
alyzed patients were HBs Ag positive and also presented
anti-HBs antibodies; 11 other patients were HBs Ag negative
and presented spontaneous anti-HBs antibodies; the remaining
patients who were negative for HBs Ag and specific antibodies
underwent vaccination.
In the case of hemodialyzed patients blood samples were
collected immediately before dialysis. For nine hemodialyzed
patients samples were collected twice, before dialysis and
shortly after the end of the dialysis session.
As a control population, 23 age- and sex-matched normal
volunteers were studied. All blood samples were collected in
heparin containing vacutainers. Plasma was recovered and
frozen at —80°C until tested, and the cell pellet including red
and white blood cells was used to recover the mononuclear
cells.
Cellular preparations
Peripheral blood mononuclear cells (PBM) were isolated by
centrifugation at 400 x g on a Ficoll-Paque (Pharmacia, Upp-
sala, Sweden) gradient. PBM were recovered at the interface
and washed twice in Hanks' balanced salt solution (HBSS;
Eurobio, Paris, France). When required, PBM were separated
into T cells and non-T cells by rosetting with neuraminidase
(Behringwerke, Marburg, FRG) treated sheep erythrocytes
[27]. Rosetting E lymphocytes thus obtained contained 92 to
95% OKT3 cells as assessed by indirect immunofluorescence.
Immunofluorescence test
Monoclonal antibodies used for labeling assays were OKT3
(IgG2a), OKT4 (IgG2b), OKT8 (IgG2a) (Ortho Pharmaceutical
Corporation, Raritan, New Jersey, USA) that respectively
recognize total human T cells (CD3), helper/inducer (CD4)
and cytotoxic/suppressor T cells (CD8) [30]. In addition, Tact
T cells were detected using lOT l4a (Immunotech, Marseille,
France), a rat monoclonal antibody that recognizes the human
Tac antigen (that is, the IL-2 receptor). This antibody was used
with OKT3 in double labeling experiments.
Indirect immunofluorescence was performed as previously
described [311 on freshly stimulated E cells or following
incubation with recombinant IL-2. Briefly, the cells (10 to 20 x
106/ml) were incubated for 30 minutes at 4°C with appropriate
dilutions of OKT3, OKT4 and OKT8. After two washes in cold
HBSS containing 5% fetal calf serum (FCS) and 0.2% sodium
azide, the cells were labeled for 30 minutes at 4°C with
fluorescein (FITC)-conjugated goat anti-mouse IgG antiserum
(Nordic, Tilburg, The Netherlands). Following washing and
resuspension, one drop was examined under a Leitz Dialux
microscope equipped for epifluorescence and 200 cells per slide
were counted. In double labeling experiments cells were first
incubated with a mixture of OKT3 and IOTl4a. Cells were then
washed and labeled with a mixture of rhodamine (TRITC)-
labeled goat anti-mouse IgG antiserum (Nordic, Tilburg, The
Netherlands) and FITC-labeled mouse anti-rat, K light-chain
monoclonal antibody (Immunotech) to detect OKT3 and
IOTl4a binding, respectively.
Results were expressed as percentage values of each given T
cell subset with respect to the total number of mononuclear
cells counted and as % CD4/% CD8 cell ratio.
Finally the percentage of doubly labeled CD3 Tack lympho-
cytes was expressed by reporting the number of single and
doubly labeled cells to that of all mononuclear CD3 cells
scored
% CD3Tac cells = ____________________
Mitogen-induced interleukin 2 production and proliferation
Culture medium was RPMI 1640 (Gibco, Paisley, Scotland,
UK) supplemented with penicillin (100 units per ml), strepto-
mycin (100 sg/ml), and FCS (2%). E cells were adjusted to 1
x 106 cells per ml distributed (I mI/well) in 24-well LiMbro
culture plates (Falco) and stimulated with 1 jsg of PHA-P
(Pharmacia) per ml. Supernatants were collected after 48 hours
of culture (in humidified 95% air/5% CO2 at 37°C), centrifu-
gated, sterilized by filtration (45-sm pore size), and stored at
—20°C until tested for IL-2 activity.
In parallel the capacity of E cells to proliferate following
PHA stimulation was also assessed. E cells were cultured in
flat-bottomed LiMbro microplates (0.2 x l0 cells in 0.2 ml of
complete culture medium) in presence of 0.4 tg/ml of PHA-P.
Proliferation was assayed after 72 hours of culture by means of
a 16-hour [3H] thymidine incorporation. Results were expressed
by means of the proliferation index that was calculated as
follows:
cpm (cells + PHA) — cpm (cells — PHA)
cpm (cells — PHA)
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IL-2 titration
Culture supernatants were thawed and tested for their IL-2
activity on the IL-2 dependent, murine-cytotoxic T-cell line,
CTLL-2. Briefly, 4 x l0 cells were cultured in round-bottomed
microplates in the presence of serial dilutions of the test
supernatants. The proliferation was analyzed after 74 hours by
means of MTT staining as described elsewhere [32]. Units were
calculated by comparison with the proliferative activity of serial
dilutions of a reference supernatant containing by definition I
unit per ml (that corresponds to 3.6 international NIH units and
is produced by 48-hr PHA stimulation of normal PBM) [33]. The
IL-2 concentration of each supernatant was calculated by using
a probit program.
In 22 patients soluble phase radioimmunoassay (RIA) was
performed in parallel with the biological assay. The RIA kit was
provided by Medgenix (Fleurus, Belgium). Briefly, 100 ui of the
samples to be tested (in duplicate at serial dilutions) were
incubated with 100 p1 of the supplied rabbit anti-human IL-2
polyclonal antiserum for 18 to 24 hours at room temperature.
Then 100 d of the tracer 125 I-IL-2 was added to each tube and
incubated for four hours at room temperature. Following the
addition of anti-rabbit gamma-globulins diluted in a buffer
containing polyethylene glycol, cellulose and Tween 20, the
samples were centrifuged 15 minutes at 1500g. The supernatant
was aspirated and the radioactivity of the pellet assessed in a y
counter (LKB, Paris, France). In this RIA two reference
preparations were used to set the standard curve, namely, the
same natural IL-2 supernatant used in the biological assay and
human recombinant IL-2. The bound radioactivity, that is, the
percentage of 125 I-IL-2 bound, was determined as follows:
B/Bo (cpm standard or sample) — (cpm nonspecific)(cpm zero standard) — (cpm — nonspecific)
where cpm (nonspecific) equals buffer + tracer, and cpm (zero
standard) is the sample containing OU/ml of IL-2. The mean
radioactivity introduced/tube ranged 20,000 cpm; the cpm of the
zero standard ranged to 400 cpm; the cpm of the nonspecific
sample ranged to 10,000 cpm.
The B/Bo x 100 values for each standard point were plotted
as a function of the IL-2 concentration using semi-logarithmic
paper. IL-2 concentrations in test samples were then deduced
by extrapolation to the standard curve. The sensitivity of this
assay was 0.5 U/mI, that is, 0.05 U/tube (according to the
international NIH standard). In our laboratory this RIA was
used in parallel to the conventional CTLL-2 assay to test 200
culture IL-2 containing supernatants obtained by stimulating T
cells either from normal controls or patients presenting different
pathologies. In all cases a perfect correlation between results
obtained with those two tests was observed.
Sensitivity of T cells to exogenous IL-2
Freshly isolated E rosetting T cells were cultured in triplicate
(0.5 x 106/ml) in round-bottomed microtiter plates (0.2 ml per
well) in RPMI 1640 medium containing antibiotics, and 10%
FCS and 1 or 3 U/mI of recombinant IL-2 (Sandoz, Wien,
Austria). Proliferation was assayed after 48 hours of culture by
means of a 16-hour [3H] thymidine incorporation assay (CEA,
Gif-sur-Yvette, France).
Soluble IL-2 receptor
Detection of soluble IL-2 receptors in plasma and culture
supernatants was performed by means of an already described
ELISA assay [34]. Briefly, Immulon 1 flat-bottomed 96-well
microtiter plates (Dynatech Laboratories, Alexandria, Virginia,
USA) were coated with 150 p1 of purified anti-Tac [29] at I
g/ml in carbonate buffer, pH 9.6 or carbonate buffer alone as
a background control, and left overnight. After washing, 100 p1
of each plasma sample was added to the coated and control
wells for a two hour incubation. Following washing 100 p1 of a
1/4000 dilution of FITC-conjugated 7G7/B6 [35] (that is, a
monoclonal antibody recognizing an epitope of the IL-2 recep-
tor distinct from that recognized by anti-Tac) in phosphate-
buffered saline containing 1% FCS was added to all wells. After
an additional two hour incubation, the plates were washed and
100 p1 of a 1/1000 dilution of alkaline phosphatase-conjugated
rabbit anti-FITC were added. p-Nitrophenyl phosphate (1 mgI
ml) was used as the enzyme substrate. Absorbance of the wells
was determined after 30 minutes at 405 mm using a Titertek
ELISA reader (Flow Laboratories, Rockville, Maryland,
USA). A reference reagent consisting of the cell-free superna-
tant of a normal IL-2-dependent human I cell line, four days
after stimulation with 10% IL-2 (Cellular Products, Buffalo,
New York, USA), was used in all of these studies. The
undiluted supernatant was assigned a value of 1000 IL-2R U/mI,
and the absorbance values, determined by ELISA, of serial
dilutions of this supernatant were used to generate a reference
curve.
Statistical analysis
Statistical analysis of the results was performed by means of
the Students 1-test for paired or unpaired data.
Results
IL-2 Activity
IL-2 activity was evaluated in the supernatants collected
from PHA stimulated E rosetting T cell cultures by means of the
biological assay using the murine CTLL-2 line. In parallel, in
order to confirm both the sensitivity and specificity of the
biological assay, a soluble phase RIA using human '251-IL-2 as
a tracer, was used in 20 of the uremic hemodialyzed and
non-hemodialyzed patients. Figure 1 shows that a significant
correlation was found when comparing experimental values
obtained with these two tests. At the dose of mitogen used (2
/Lg/ml of PHA) the mean IL-2 activity present in supernatants
collected from normal controls' E rosetting T cells was 2.49
0.22 U/mI (mean sEM).
In parallel, the cell proliferation in the same cultures used to
evaluate PHA induced IL-2 activity was also studied. In normal
controls the observed mean proliferation index was 184.8
22.4 (mean SEM).
Uremic non-hemodialyzed patients. Mean IL-2 activity ob-
served in the 11 patients presenting with end-stage chronic renal
failure before the institution of dialysis replacement therapy
was significantly decreased as compared to normal controls'
values (mean SEM 0.85 0.24 vs. 2.49 0.22 U/mI; Fig. 2).
Six out of these 11 patients (50%) presented an IL-2 activity
0.3 U/mI, that is, levels close to background.
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• alysis was similar to the one found in non-hemodialyzed pa-
tients (mean SEM 0.93 0.12 vs. 0.85 0.24 U/mI; Fig. 2)
• with, here, again a significant decrease compared to normal
• controls' values (2.49 0.22 U/mI; Fig. 2).
When compared to normal controls, uremic hemodialyzed
patients showed a significantly decreased mean PHA-induced
r = 0843 cell proliferation index: mean SEM 79.5 17.2 versus 184.8
• • p< 22.4, P < 0.001. The difference was not significant when
• : comparing the indexes observed in non-hemodialyzed and
hemodialyzed patients.
.. The fact that similar results were observed when using either
the biological assay or the soluble phase RIA allowed to
0 0.2 0.4 0.6 0.8 1 1.2 exclude that any soluble factor present in the analyzed super-
natants interfering with the CTLL-2 biological assay was re-
sponsible for the low IL-2 activities detected. Further stressing
this point the addition of serial dilutions of culture supernatants
from uremic patients presenting low IL-2 activities, to recom-
binant or natural IL-2 reference preparations did not modify
their IL-2 activity as assessed by the CTLL-2 assay.
Effect of dialysis session. In nine of the uremic hemodialyzed
• patients studied, PHA-induced IL-2 activity and cell prolifera-
tion were assessed in cultures from T cells collected before and
• just after a dialysis session. No significant difference was noted
when comparing the data by means of the Student's t-test for
paired data (Table 1).
Fig. 2. Interleukin-2 activity in stimulated T cell culture supernatants.
Values observed in normal controls (column A); uremic non-hemodia-
lyzed (non-HD) patients (column B); uremic hemodialyzed (HD) pa-
tients (column C). For each group of patients the horizontal bars
represent mean values. The detailed mean SEM values are reported
for all the 3 groups analyzed.
In these patients mean PHA-induced cell proliferation index
was decreased although not significantly as compared to normal
controls: 116.1 39.0 versus 184.8 22.4 (mean sEM).
Hemodialyzed patients. The IL-2 activity detected in culture
supernatants from uremic patients undergoing regular hemodi-
Spontaneous expression of IL-2 receptorby peripheral T cell
(in the absence of mitogen activation)
Freshly collected E T cells that were not submitted to any
prior in vitro stimulation were studied for their IL-2 receptor
expression. Two different methods were used in parallel allow-
ing the detection of two distinct types of IL-2 binding sites
known to possess variable affinity for the IL-2 molecule,
namely, high and low affinity IL-2 receptors [36]. Firstly,
immunofluorescence labeling using the IOTl4a monoclonal
antibody was used to detect the Tac antigen expressed by the a
chain of the IL-2 receptor that is shared by both high and low
affinity receptors [36]. Double staining using a mixture of OKT3
(that specifically recognizes T cells) and IOTl4a allowed the
direct detection of T cells bearing the Tac antigen. Secondly,
since only high affinity receptors trigger cell proliferation fol-
lowing IL-2 binding, such receptors were studied by evaluating
the capacity of non-stimulated E T cells to proliferate in
presence of exogenous recombinant IL-2.
The proportion of normal freshly collected E cells express-
ing the Tac antigen was 2.15 0.38% (mean SEM; Fig. 3).
After short term (48 hrs) in vitro exposure of cells to exogenous
recombinant IL-2 Tac antigen was expressed on 3.17 0.80%
of the cells recovered (Fig. 3). Results obtained when evaluat-
ing thymidine incorporation under the same culture conditions
are detailed in Figure 4.
Uremic non-hemodialyzed patients. Freshly collected E ro-
setting lymphocytes from uremic non-hemodialyzed patients
showed a proportion of Tack T cells that was significantly
increased as compared to normal controls' values mean SEM:
5.69 0.63% versus 2.15 0.38% (Fig. 3).
Moreover, the spontaneous proliferative response of these T
cells was also significantly higher than the one recorded in
normal controls (Fig. 4). Thus, 6 out of the 20 patients studied
0.9
. 0.6.
0.4
0.2
0
Biological assay, U/mi
Fig. 1. Correlation between values observed for IL-2 levels in culture
supernatants from uremic patient's stimulated T cells as assessed by a
biological assay using the CTLL-2 line and a radioimmunoassay using
human iodinated IL-2. Results were expressed in U/mI as referred to 2
different reference preparations (Methods).
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Table 1. Effect of the hemodialysis session on peripheral T cell phenotypes and function
Patients
IL-2 activity Mitogenic response % CD4+/%CD8+ ratio
Pre-HD Post-HD Pre-l-ID Post-HD Pre-HD Post-HD
CHA 1.4 1.3 191.4 70.8 0.81 1.05
SAL 1 1 227.5 251.9 0.81 0.86
IPP 0.5 0.7 278.1 164.2 1.37 1.61
ROB 2.4 2.1 63.0 47.1 2.54 2.61
MON 0.6 0.5 58.1 97.2 — —
NDA 0.6 0.6 24.3 32.8 1.23 1.46
BAY 1.1 1.4 32.7 33.8 2.06 1.8
BAU 0 0 131.4 66.9 1.02 0.94
KOU 1.5 1.3 17.3 25.8 1.35 1.25
For all parameters no significant difference between pre-HD and post-HD values was assessed by using the Student's t test for paired data.
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— Fig. 3. Percentage values of T cells
expressing the IL-2 receptor a chain as
assessed by labeling with an anti-Tac
£ monoclona! antibody. Results are detailed for
£ normal controls, uremic non-hemodialyzed
(non-HD) and hemodialyzed (HD) patients.
Cells were studied as collected from
* peripheral blood at time 0 (column a) orfollowing 48 hrs of culture in presence of 0
U/mi (column b) or 2 U/mI (column C) of
human recombinant IL-2. The horizontal bars
represent mean values that are as follows:
Normal controls: (a) 2.15 0.38%; (b) l.86
0.41%; (c) 3.17 0,80%. Non-HD uremic
____________
patients: (a) 5.69 0.63%; (b) 5.35 0.38%;
(c) l2.14 0.95%. HO uremic patients: (a)
7.11 0.81%; (b) 9.58 1.41%; (C) 19.08
HO uremic patients 1.98%.
showed a thymidine incorporation at 48 hours of culture in
medium alone (in the absence of any stimulation) that exceeded
the mean value 2 SD exhibited by normal T cells. When these
patients' cells were cultured for 48 hours in presence of
recombinant IL-2, a significantly higher response than the one
found with normal E cells was noted (Fig. 4). Increasing the
amounts of exogenous IL-2 added to the cultures did not
significantly influence the proliferative response (Fig. 4).
Uremic hemodialyzed patients. The proportion of peripheral
Tact T cells in uremic hemodialyzed patients was significantly
increased as compared to normal controls (mean SEM 7.11
0.81% vs. 2.15 0.38%). The spontaneous proliferative re-
sponse of hemodialyzed T cells was also significantly higher
than the one observed in normal controls (Fig. 4). This mean
spontaneous proliferation was also higher than the one ob-
served with uremic non-hemodialyzed patients' E cells, al-
though in this case the difference was not statistically significant
(Fig. 4). Lastly, addition of exogenous IL-2 to the cultures
revealed an abnormally high sensitivity of non-stimulated he-
modialyzed patients' T cells to the lymphokine, with a mean
proliferation that was significantly higher in hemodialyzed
patients as compared to both normal controls and uremic
non-hemodialyzed patients (Fig. 4). At variance with non-
hemodialyzed patients a dose-dependent IL-2 induced prolifer-
ative response was observed in hemodialyzed patients (Fig. 4).
Effect of the hemodialysis session. As detailed on Table 2 the
dialysis session by itself did not influence the expression of IL-2
receptor on hemodialyzed patients' peripheral T cells. Thus,
similar phenotypic and functional patterns were found when
analyzing peripheral T cells in nine different patients before and
after the hemodialysis session. None of the parameters men-
tioned above namely, Tac expression either on fresh T cells or
on T cells cultured in presence of IL-2, spontaneous T cell
proliferation and the increased sensitivity to exogenous IL-2
showed any significant modification when analyzed by means of
the Student's I-test for paired data (Table 2).
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Fig. 4. Pro!ferative capacity of peripheral blood T cells from normal
controls, uremic non-hemodialyzed (non-HD) and hemodialyzed (ND)
patients cultured for 48 hrs in presence of I or 3 U/mI of human
recombinant IL-2. Results are expressed as counts per minute (cpm).
The horizontal bars represent mean values that are as follows (mean
SEM):
Normal controls
o U/mI 207.6 22.6 (1)
I U/mI 1647.5 244.5 (2)
3 U/mI 2508.3 346.3 (3)
Non-RD uremic patients
0 U/mI 402.6 59.6 (4)
I U/mI 3501.5 349.4 (5)
3 U/mI 3915.3 386.9 (6)
IID-uremic patients
0 U/mI 708.3 151.4 (7)
I U/mI 5438.0 730.0 (8)
3 U/mI 7075.3 810.1 (9)
Statistical comparison: 1 and 4) P < 0.003; I) and 7: P < 0.003; 2) and
5): P < 0.0002; 2) and 8): P < 0.0001; 3) and 6): P < 0.01; 3) and 9): P
<0.003; 6) and 9): P < 0.003.
Soluble circulating IL-2 receptor
We detected a soluble form of the Tac antigen in the patient
and control plasma by means of a specific ELISA. The physi-
cochemical properties of this soluble form of the IL-2 receptor,
shown to be released from different types of normal or tumoral
Tack cells have already been reported [34, 37]. Results are
expressed in U/mi according to a reference curve set up by
using as a standard a cell free supernatant of an IL-2 dependent
human T cell line.
As shown on Figure 5 uremic non-hemodialyzed and hemo-
dialyzed patients exhibited circulating levels of soluble IL-2
receptor that were significantly increased as compared to nor-
mal control values. In six cases, plasma samples were analyzed
before and after the dialysis session and no major modification
of serum soluble IL-2 receptor was noted (Fig. 5).
The percentage values of total T cells (CD3), helper-inducer
(CD4) and cytotoxic/suppressor (CD8) T cells was analyzed
by labeling of E rosetting T lymphocytes with specific mono-
clonal antibodies (that is, OKT3, OKT4 and OKT8). The %
CD4/% CD8 ratio was 1.37 0.11 (mean SEM) in normal
controls, 2.10 0.58 in uremic non-hemodialyzed patients and
1.51 0.12 in uremic hemodialyzed patients. Three values
without any statistically significant difference when compared
by using the Student's t-test.
Furthermore, as detailed in Table I, the dialysis session did
not provoke, at least in the nine patients analyzed, any signif-
icant acute modification in the proportions of the different T cell
subsets analyzed. Uremic patients included in this study were
lymphopenic, a finding in complete accordance with several
other reports [1—3, 38], including ours [27]. Thus, absolute
counts of the various T cell subsets were decreased as com-
pared to controls (data not shown) but, when results were
expressed as percentage values the proportions between the
main regulatory T cell subsets were normal.
Discussion
Phenotypic and functional parameters related to T cell acti-
vation have been analyzed in a series of clinically homogeneous
uremic patients undergoing or not chronic hemodialysis. We
concentrated our attention on the production and receptor
targeting of a major T cell derived lymphokine, namely inter-
Ieukin-2 (IL-2), since our preliminary reported data [27] had
indicated that both these parameters were severely affected in
hemodialyzed patients. Moreover, IL-2 is essential for appro-
priate cell cooperation in delayed type hypersensitivity reac-
tions known to be greatly impaired in uremic patients. Thus,
any abnormality in the bioavailability of IL-2 may represent a
major pathophysiological element to explain the secondary
immunodeficiency associated with chronic uremia.
Results obtained in this study totally confirm on a large series
of 23 hemodialyzed patients the observations made in our first
report [27] showing abnormally increased proportions of circu-
lating T cells spontaneously expressing the IL-2 Rec.
IL-2 Rec is expressed at the surface of activated T cells under
different molecular forms. Binding studies using radiolabeled
IL-2 have demonstrated that T cells may express at least two
sorts of IL-2 binding sites presenting different affinities for IL-2,
that is, high (Kd = 10 M) and low (Kd = 10—8 M) affinity
receptors [36]; only high affinity receptors can trigger IL-2
mediated cell proliferation [36, 39]. Biochemical studies al-
lowed the characterization of two different polypeptide chains
termed a (55 kDa) and /3 (75 kDa) [40—431. Low affinity
receptors correspond to the exclusive expression of the a chain
at the cell surface; IL-2 binding to these sites do not lead to
endocytosis of the growth factor-receptor complex [43]. At
variance, both a and /3 chains (noncovalently linked) are needed
for the expression of high affinity receptors able to mediate IL-2
internalization [39—43]. Exclusive expression of the /3 chain (a
situation only described for some cell lines [43]) can mediate
internalization of IL-2 and cell growth [43]. Only the a chain
expresses the Tac epitope identified by the anti-Tac or similar
monoclonal antibodies [29]. Thus these monoclonal antibodies
will target both high and low affinity receptors. Thus, by
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Table 2. Effect of the hemodialysis session on preactivated peripheral T lymphocytes
Patients
% circulating Tack cells
Sensitivity to exogenous IL-2
Tac T cells
%
Proliferation
cpm
Post-HD Pre-HD Post-HDPre-HD Post-HD Pre-HD
CHA
SAL
IPP
ROB
MON
NDA
BAY
BAU
KOU
13.8 14.6
13.5 12.1
7.8 12.8
16.7 19.5
6.6 7.4
15.2 12.8
7.3 6.3
7.7 8.6
7.6 12.4
34.1
18.9
23.4
49.3
22.9
21.0
15.6
27.0
28.2
26.6 9132
23 8962
29.3 3242
54 6278
25.6 9651
20.7 12485
14.4 15104
24.7 10038
33.3 6108
8220
5334
4728
7016
9500
13934
14682
12007
7953
For all parameters no significant difference between pre.HD and post-HD values was assessed by using the Student's t-test for paired data.
+
Normal Non-HO uremic Before After
controls patients HD HD
HD uremic patients
FIg. 5. Circulating soluble IL-2 receptor levels as detected by means of
a specific ELISA in the serum of normal controls, non-hemodialyzed
(non-HD) or hemodialyzed (HD) patients. Six hemodialyzed patients
are reported whose serum was tested before and after the dialysis
session. The horizontal bars represent mean values that are as follows:
Normal controls, 253.5 29.3 U/mI; Non-lID uremic patients, 3220.7
832.4 U/mI; HD uremic patients, 4036.0 947.1 U/mI.
applying in parallel an immunofluorescence assay with an
anti-Tac monoclonal antibody and a functional test defining the
capacity of Tack cells to proliferate in presence of exogenous
recombinant IL-2 alone, one may infer which type of IL-2
receptor (high or low affinity) is expressed by a given popula-
tion. Direct binding studies using radiolabeled IL-2 were im-
possible to perform on hemodialyzed patients due to the high
number of purified IL-2 Rec cells that would have been
needed.
The results obtained confirmed that in hemodialyzed patients
peripheral T cells that spontaneously express the Tac antigen
also exhibit an abnormally increased sensitivity to exogenous
IL-2. Thus, at variance with what was observed in normal
controls, peripheral T cells from hemodialyzed patients are able
to proliferate in short term cultures in presence of recombinant
IL-2. This increased proliferation is fully paralleled, in the same
cultures, by the presence of impressively high proportions of
IL-2 Rec positive cells. These results strongly suggest that, at
least part of this particular T cell subset is spontaneously
expressing in vivo high affinity IL-2 Rec.
The plasma of the same patients was analyzed for the
presence of the soluble form of the Tac antigen since an
increased IL-2 Rec expression may lead to its release in the
circulation. In all hemodialyzed patients studied, levels of
soluble Tac antigen were increased 10- to 20-fold as compared
to normal controls. This increase in circulating Tac may be
related to the increased expression of Tac by T cells, although
one cannot exclude that soluble Tac also represents a retention
product. Although this soluble form of the IL-2 Rec is able to
bind IL-2 [44], it is not known whether it represents a marker of
abnormal T cell activation or if it can really interfere with
regulatory processes.
A significantly decreased IL-2 production was found in 48
hours culture supernatants from stimulated hemodialyzed pa-
tients' T cells; 56% of patients showed IL-2 levels < lU/mi.
Similar data, that are concordant with our previous results [27],
have also been described by other groups [17, 18, 45]. Since
identical results were obtained by using either the conventional
biological IL-2 assay (using the murine, CTLL-2 line) or a
soluble phase RIA (using radiolabeled human IL-2) one may
exclude the possibility that the defect observed could be related
to a soluble inhibiting material present in the culture superna-
tants and interfering with the biological assay. Moreover, we
have also shown that the significantly lower IL-2 activity
observed is not related to an excessive production of pros-
taglandins E2 (PGE2) by remnant monocytes present in the
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culture [27] (monocytes can depress IL-2 production by releas-
ing PGE2 which in turn activate suppressor I lymphocytes
[46]). This result was confirmed by others using a different
technical approach [451.
The abnormal mitogen-induced 11-2 activity could be related
either to defective production and/or to increased absorption of
the lymphokine by activated Tack T cells. Supporting this latter
hypothesis are the results showing that, even in low amounts,
IL-2 significantly up-modulates IL-2 Rec expression in hemo-
dialyzed patients' T cells, establishing a vicious circle. How-
ever, if absorption was the only mechanism one would expect
to observe either a normal or an increased PHA induced
proliferation. Since this is not the case namely, a decreased
response is generally observed, the presence of an associated T
cell defect cannot at this point be ruled out.
Recently it has been suggested that the impaired T cell
response could be related to monocyte dysfunction [181. How-
ever, results concerning this issue are still controversial. Some
authors describe normal or increased IL-I production from
stimulating monocytes in hemodialyzed patients [47, 48] while
others found defective production [49]. Moreover, some data
may also suggest that monocyte related factors, different from
IL-l, could also be implicated [18].
Results obtained when extending the study to a series of 20
patients presenting end stage uremia before the beginning of
hemodialysis revealed that similar features of T cell activation
were present, although to a lesser degree than in hemodialyzed
patients. Thus, peripheral Tact T cells and circulating IL-2 Rec
levels were abnormally high in these patients as compared to
normal controls, although the values were lower than those
observed in hemodialyzed patients. Similarly, increased T cell
sensitivity to exogenous IL-2 was evidenced that was, how-
ever, less striking than the one exhibited by uremic hemodia-
lyzed patients. Finally, in uremic non-hemodialyzed patients
IL-2 activity in stimulated T cell culture supernatants and in
association with a subnormal PHA proliferative responsiveness
was decreased.
These results suggest that even before starting renal replace-
ment therapy by means of hemodialysis, the immunodeficiency
of chronic uremia is already associated with phenotypical and
functional signs of T cell preactivation. Moreover T cell preac-
tivation is significantly accentuated by hemodialysis, indepen-
dently from the kind of membrane used.
No major modifications could be evidenced in any of the
phenotypical or the functional tests performed in the nine
uremic hemodialyzed patients were studied prior to the onset
and at the end of the hemodialysis session. This is at variance
with other reports in the literature describing modifications in
the proportions of the various T cell subsets [50], or of their
functional capacity [51] during or immediately after the dialysis
session. It is difficult to give any reliable explanation for this
discrepancy although one may assume that variabilities in
patient selection represent the major factor.
To conclude, the data presented in this work suggest that
uremia per se induces a state of in vivo T cell preactivation
whose intensity is exacerbated by hemodialysis. Moreover,
they underline that the abnormality of IL-2 production and
receptor targeting, observed both in uremic hemodialyzed and
non-hemodialyzed patients, is central to the state of immuno-
deficiency induced by chronic renal failure.
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